Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Change in Accured Expenses (2023 - 2025)

Bioharvest Sciences has reported Change in Accured Expenses over the past 3 years, most recently at -$979000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 225.25% year-over-year to -$979000.0; the TTM value through Dec 2025 reached $482000.0, down 53.65%, while the annual FY2025 figure was $482000.0, 53.65% down from the prior year.
  • Change in Accured Expenses was -$979000.0 for Q4 2025 at Bioharvest Sciences, down from $59000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.1 million in Q3 2024 and bottomed at -$979000.0 in Q4 2025.
  • The 3-year median for Change in Accured Expenses is $215500.0 (2024), against an average of $222400.0.
  • The widest YoY moves for Change in Accured Expenses: up 520.15% in 2025, down 225.25% in 2025.
  • Over 3 years, Change in Accured Expenses stood at -$121000.0 in 2023, then plummeted by 148.76% to -$301000.0 in 2024, then crashed by 225.25% to -$979000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$979000.0 (Q4 2025), $59000.0 (Q3 2025), and $839000.0 (Q2 2025) per Business Quant data.